Difference between revisions of "Crenolanib (CP-868,596)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
Line 1: | Line 1: | ||
− | + | ==Mechanism of action== | |
+ | From the NCI Drug Dictionary: An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation. | ||
− | =Preliminary Data= | + | ==Preliminary Data== |
# Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. [http://jco.ascopubs.org/content/27/31/5262.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/19738123 PubMed] | # Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. [http://jco.ascopubs.org/content/27/31/5262.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/19738123 PubMed] | ||
+ | |||
+ | ==Also known as== | ||
+ | *'''Code name:''' CP-868-596 | ||
[[Category:Drugs]] | [[Category:Drugs]] |
Revision as of 01:57, 14 December 2020
Mechanism of action
From the NCI Drug Dictionary: An orally bioavailable small molecule, targeting the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Crenolanib binds to and inhibits PDGFR, which may result in the inhibition of PDGFR-related signal transduction pathways, and, so, the inhibition of tumor angiogenesis and tumor cell proliferation.
Preliminary Data
- Lewis NL, Lewis LD, Eder JP, Reddy NJ, Guo F, Pierce KJ, Olszanski AJ, Cohen RB. Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers. J Clin Oncol. 2009 Nov 1;27(31):5262-9. Epub 2009 Sep 8. link to original article PubMed
Also known as
- Code name: CP-868-596